Clinical trials
Lymphoma, B-Cell clinical trials
Below are recruiting lymphoma, b-cell clinical trials, each written for real people, not researchers. We’re tracking 534 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07652580Recruiting
Toxins, immunity, and B-cell lymphoma
This study looks at how exposure to toxins might affect your immune system if you have B-cell non-Hodgkin lymphoma. You'll provide blood and skin samples, plus have your genes sequenced, to help researchers find links between environmental exposures and lymphoma.
Bethesda, MarylandAges 4 years+ - NCT06693973RecruitingEarly Phase 1
AcNK-Sup003 cell therapy for relapsed B-cell lymphoma
This early-phase trial tests a new immune cell treatment called AcNK-Sup003 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior therapy. The goal is to see if it is safe and effective.
Wuhan, HubeiAges 18 years+ - NCT05806099RecruitingPhase 1/Phase 2
Study of MBS303 for CD20-positive B-cell lymphoma that returned
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
BeijingAges 18 years+ - NCT06566586RecruitingPhase 2
Study of TQB3702 plus immunochemotherapy for B-cell lymphoma
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07620314RecruitingPhase 1
Testing a new cell therapy for B-cell lymphoma
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07616089RecruitingPhase 1
Study of a new pill for advanced blood cancers
This trial tests a new pill for people with certain blood cancers that have not gotten better with standard treatments. It aims to see if the drug is safe and works, and it may help shrink tumors or slow the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07609862RecruitingPhase 1/Phase 2
Rocbrutinib and Lacutoclax for B-Cell Blood Cancers
This trial tests a combination of two new drugs (rocbrutinib and lacutoclax) to treat B-cell lymphomas and leukemias. The goal is to see if this combination works better than standard treatments, especially for patients whose cancer has come back or stopped responding to previous therapy.
TianjinAges 18 years+ - NCT07606937RecruitingEarly Phase 1
Automated CAR-T cell therapy for relapsed large B-cell lymphoma
This early-stage trial tests an automated version of axicabtagene ciloleucel (a CAR-T cell therapy) for large B-cell lymphoma that has come back or stopped responding to initial chemotherapy. CAR-T therapy uses your own immune cells, modified in a lab to fight cancer cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07608978RecruitingPhase 2
New drug combination for untreated aggressive lymphoma
This study tests a combination of five drugs (including a targeted therapy called polatuzumab vedotin) for patients with a specific type of aggressive lymphoma (DLBCL) that has never been treated before. The goal is to see if this combination works better and is safe for certain subtypes of this cancer.
Nanjing, JiangsuAges 18 years+ - NCT07609030Recruiting
Brain Training During CAR-T Cell Cancer Treatment
This study tests whether special brain exercises can help protect thinking and memory skills during CAR-T cell therapy—a newer cancer treatment for certain blood cancers. Researchers want to see if training your brain during treatment reduces side effects on memory and mental function.
Columbus, OhioAges 18 years+ - NCT07603479RecruitingPhase 1
Testing JL19001 for Advanced Cancers and Lymphoma
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06716164RecruitingEarly Phase 1
Experimental car-t cell therapy for relapsed b-cell lymphoma
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hangzhou, ZhejiangAges 19–70 - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT07593482RecruitingPhase 2
Conditioning chemo before CAR-T for large B-cell lymphoma
This trial compares two standard chemotherapy combinations (bendamustine or fludarabine plus cyclophosphamide) given before a CAR-T cell treatment to see which one helps the CAR-T cells work better and causes fewer side effects.
AarauAges 18 years+ - NCT06725524RecruitingPhase 1
New drug for B-cell lymphoma that returned after treatment
This trial tests a new drug called JMT601 for people with a type of B-cell lymphoma that came back or didn't respond to at least two previous treatments. The drug targets a protein on the cancer cells to help your immune system fight the disease.
ShanghaiAges 18–70 - NCT07572136RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell leukemia
This trial tests a new type of CAR T-cell therapy—a treatment that uses your own immune cells engineered to fight leukemia cells. It is designed for patients with B-cell acute lymphoblastic leukemia (ALL) that has come back or stopped responding to standard treatments, and whose leukemia cells have a specific marker called TSLPR.
Bethesda, MarylandAges 18–120 - NCT07570017RecruitingPhase 1
Rocbrutinib Plus Chemotherapy for Resistant B-Cell Lymphoma
This study tests whether combining a new drug called rocbrutinib with standard chemotherapy (R-GemOx) works better for patients whose diffuse large B-cell lymphoma (a type of blood cancer) has stopped responding to previous treatments. Researchers hope this combination may help patients who have limited options.
Guangzhou, GuangdongAges 18 years+ - NCT07570823RecruitingPhase 3
SCTB35 Plus Chemotherapy for Relapsed Lymphoma
This study tests a new drug called SCTB35 combined with two common chemotherapy drugs (gemcitabine and oxaliplatin) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatment. The goal is to see if this combination is safe and helps shrink the cancer.
BeijingAges 18–80 - NCT07564453RecruitingPhase 2
Immunotherapy plus chemotherapy for newly diagnosed B-cell leukemia
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
Suzhou, JiangsuAges 15–65 - NCT06735495RecruitingPhase 1/Phase 2
Two-target CAR T cells for relapsed B-cell blood cancers
This trial tests a new type of immunotherapy that uses your own immune cells engineered to recognize two cancer targets (CD19 and CD22) to treat B-cell blood cancers that have come back or not responded to standard treatments. It may offer a treatment option when other therapies have stopped working.
Wuhan, HubeiAges 3–75 - NCT06026488Recruiting
Study of DLBCL by genetic subtype
This study looks at how different genetic types of diffuse large B-cell lymphoma (DLBCL) respond to treatment in real-world settings. It may help doctors understand which treatments work best for your specific subtype.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07548697RecruitingEarly Phase 1
Safety study of CT1182 for relapsed B-cell lymphoma
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
Wuhan, HubeiAges 18–75 - NCT06071871RecruitingPhase 2
A trial of 3 drugs before or after CAR-T for lymphoma
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
LondonAges 18 years+ - NCT07538635RecruitingPhase 2
CAR-T cells plus stem cell transplant for aggressive lymphoma
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
Hangzhou, ZhengjiangAges 18 years+
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma, b-cell?
- Yes. Clin2 currently lists 534 recruiting lymphoma, b-cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma, b-cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma, b-cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.